SCHEMBL74963

SCHEMBL74963

O=C(O)N1CCCCC1O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.37
GAA P10253 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
POLB P06746 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HTT P42858 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
DPP4 P27487 3/20 0.33
DPP8 Q6V1X1 2/20 0.33
DPP9 Q86TI2 2/20 0.33
CHRM2 P08172 2/20 0.33
CHRM4 P08173 2/20 0.33
CHRM5 P08912 2/20 0.33
CHRM1 P11229 2/20 0.33
CHRM3 P20309 2/20 0.33
FAP Q12884 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18639814 1.00 HPGD (0.37) HPGDGAACA12CA1CA2
SCHEMBL4772277 0.98 HPGD (0.37) HPGDGAACA12CA1CA2
SCHEMBL560075 0.93
SCHEMBL4028231 0.83 HPGD (0.38) HPGDGAACA12CA1CA2
SCHEMBL2354161 0.82
SCHEMBL4598253 0.79 EPHX1 (0.37) HPGDGAACA12CA1CA2
SCHEMBL5329524 0.79 HPGD (0.36) HPGDGAACA12CA1CA2
SCHEMBL10808899 0.79 CHRM2 (0.46) HPGDGAACHRM2CHRM4CHRM5
SCHEMBL5329527 0.76 KMT2A (0.37) GAACA12CA1CA2CA9
SCHEMBL3109587 0.74 GAA (0.36) HPGDGAACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-8470772-B2 Leptin agonist and methods of use Temple University—Of the Commonwealth System of Higher Education (US) 2013-06-25 US claimed
US-20110015124-A1 LEPTIN AGONIST AND METHODS OF USE Temple University of the Commomwealth System of Higher Eduacation (US) 2011-01-20 US claimed
EP-2252314-A2 LEPTIN AGONIST AND METHODS OF USE Temple University - Of The Commonwealth System of Higher Education (US) 2010-11-24 EP claimed
WO-2009108340-A2 LEPTIN AGONIST AND METHODS OF USE TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-09-03 WO claimed
JP-3912798-B2 2007-05-09 JP claimed
EP-0871653-B1 NOVEL AMINO ACID DERIVATIVES, METHODS OF PRODUCING THEM, AND PHARMACEUTICAL COMPOUNDS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA (DE) 2003-03-26 EP claimed
EP-0979827-A1 Peptides having tachykinin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same Boehringer Ingelheim Pharma KG (DE) 2000-02-16 EP claimed
JP-2000501382-A 2000-02-08 JP claimed
EP-0610487-B1 NEW AMINOACID DERIVATES, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA (DE) 1999-11-10 EP claimed
EP-0804463-A1 NEUROKININE (TACHYKININE) ANTAGONISTS BOEHRINGER INGELHEIM KG (DE) 1997-11-05 EP claimed
EP-0802922-A1 NOVEL AMINO ACID DERIVATIVES, METHOD OF PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM KG (DE) 1997-10-29 EP claimed
WO-1997017362-A1 NOVEL AMINO ACID DERIVATIVES, METHODS OF PRODUCING THEM, AND PHARMACEUTICAL COMPOUNDS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM KG (DE) 1997-05-15 WO claimed
WO-1995030687-A1 NEUROKININE (TACHYKININE) ANTAGONISTS BOEHRINGER INGELHEIM KG (DE) 1995-11-16 WO claimed
WO-1995023810-A1 NOVEL AMINO ACID DERIVATIVES, METHOD OF PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM KG (DE) 1995-09-08 WO claimed
EP-0394989-B1 Peptide compounds, process for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1994-12-21 EP claimed
EP-0610487-A1 NEW AMINOACID DERIVATES, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM KG (DE) 1994-08-17 EP claimed
WO-1994005693-A1 NEW AMINOACID DERIVATES, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM KG (DE) 1994-03-17 WO claimed
US-5164372-A Treatment of respiratory disorders, inflammation, dermatitis FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1992-11-17 US claimed
EP-0394989-A2 Peptide compounds, process for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-10-31 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 HPGD 2910/4885GAA 2187/4885CA12 3378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.